Catalent (NYSE:CTLT) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Several other equities research analysts have also issued reports on CTLT. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Stephens reiterated an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. UBS Group restated a “neutral” rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Barclays upped their price objective on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $52.46.

Catalent Price Performance

CTLT stock opened at $55.77 on Friday. The firm has a 50 day moving average of $56.83 and a 200-day moving average of $48.16. The firm has a market capitalization of $10.09 billion, a P/E ratio of -8.20, a price-to-earnings-growth ratio of 6.02 and a beta of 1.20. Catalent has a 12 month low of $31.45 and a 12 month high of $60.20. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last posted its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Catalent’s quarterly revenue was down 10.2% compared to the same quarter last year. As a group, sell-side analysts predict that Catalent will post 0.28 earnings per share for the current fiscal year.

Institutional Trading of Catalent

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Thompson Siegel & Walmsley LLC boosted its position in Catalent by 46.6% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company’s stock valued at $32,069,000 after acquiring an additional 223,944 shares in the last quarter. Vanguard Group Inc. grew its stake in Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after purchasing an additional 365,648 shares during the period. Tran Capital Management L.P. grew its stake in Catalent by 12.2% in the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after purchasing an additional 39,208 shares during the period. Hsbc Holdings PLC raised its holdings in Catalent by 43.1% in the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after purchasing an additional 58,240 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in Catalent by 240.0% during the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock valued at $1,808,000 after buying an additional 28,410 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.